Home » Stocks » IDRA

Idera Pharmaceuticals, Inc. (IDRA)

Stock Price: $2.75 USD -0.18 (-6.14%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $2.71 -0.04 (-1.46%) Oct 30, 4:09 PM

Stock Price Chart

Key Info

Market Cap 96.80M
Revenue (ttm) n/a
Net Income (ttm) -77.82M
Shares Out 35.20M
EPS (ttm) -2.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $2.75
Previous Close $2.93
Change ($) -0.18
Change (%) -6.14%
Day's Open 2.87
Day's Range 2.51 - 2.90
Day's Volume 336,217
52-Week Range 0.81 - 3.14

More Stats

Market Cap 96.80M
Enterprise Value 66.77M
Earnings Date (est) Mar 18, 2021
Ex-Dividend Date n/a
Shares Outstanding 35.20M
Float 24.06M
EPS (basic) -2.63
EPS (diluted) -2.63
FCF / Share -1.20
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 515,971
Short Ratio 2.67
Short % of Float 2.14%
Beta 2.08
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.24
Revenue n/a
Operating Income -44.34M
Net Income -77.82M
Free Cash Flow -40.28M
Net Cash 30.03M
Net Cash / Share 0.85
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -62.18%
ROE -331.34%
ROIC 308.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 5
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(176.36% upside)
Current: $2.75
Target: 7.60
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth118.73%-26.61%-94.43%6405.62%241.1%55.32%-7.84%-3.77%-99.67%-
Gross Profit1.450.660.9016.
Operating Income-46.07-60.96-66.47-38.76-48.85-38.75-18.17-19.90-25.86-17.98
Net Income-56.52-59.88-65.98-38.39-48.56-38.64-18.23-19.24-23.78-17.96
Shares Outstanding28.5526.6019.6815.9514.3910.355.493.453.453.14
Earnings Per Share-2.96-2.25-3.35-2.41-3.36-3.76-3.84-6.48-8.24-5.68
Operating Cash Flow-44.50-51.92-55.26-28.20-42.99-31.32-17.14-19.92-19.19-19.56
Capital Expenditures-0.22-0.21-0.41-0.73-1.09-0.01--0.02-0.09
Free Cash Flow-44.50-51.70-55.47-28.61-43.71-32.41-17.15-19.92-19.22-19.65
Cash & Equivalents42.7971.4311310960.1641.2329.4010.4124.8834.95
Total Debt1.06-0.210.500.760.87----
Net Cash / Debt41.7371.4311210959.4040.3629.4010.4124.8834.95
Book Value-11.1763.9910810383.5843.4032.450.7112.0233.10
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Idera Pharmaceuticals, Inc.
Country United States
Employees 36
CEO Vincent J. Milano

Stock Information

Ticker Symbol IDRA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IDRA
IPO Date January 24, 1996


Idera Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. The company was founded in 1989 and is based in Exton, Pennsylvania.